Literature DB >> 8675624

Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia.

W W Li1, M M Dammerman, J D Smith, S Metzger, J L Breslow, T Leff.   

Abstract

Overexpression of plasma apolipoprotein CIII (apo CIII) causes hypertriglyceridemia in transgenic mice. A genetically variant form of the human apo CIII promoter, containing five single base pair changes, has been shown to be associated with severe hypertriglyceridemia in a patient population. In animals and in cultured cells the apo CIII gene is transcriptionally downregulated by insulin. In this study we demonstrate that, unlike the wild-type promoter, the variant promoter was defective in its response to insulin treatment, remaining constitutively active at all concentrations of insulin. The loss of insulin regulation was mapped to polymorphic sites at -482 and -455, which fall within a previously identified insulin response element. Loss of insulin regulation could result in overexpression of the apo CIII gene and contribute to the development of hypertriglyceridemia. The variant apo CIII promoter is common in the human population and may represent a major contributing factor to the development of hypertriglyceridemia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8675624      PMCID: PMC185964          DOI: 10.1172/JCI118324

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  24 in total

1.  Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.

Authors:  H N Ginsberg; N A Le; I J Goldberg; J C Gibson; A Rubinstein; P Wang-Iverson; R Norum; W V Brown
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

2.  DNA polymorphisms of apolipoprotein A-I/C-III and insulin genes in familial hypertriglyceridemia and coronary heart disease.

Authors:  K Aalto-Setälä; K Kontula; T Sane; M Nieminen; E Nikkilä
Journal:  Atherosclerosis       Date:  1987-07       Impact factor: 5.162

3.  Deoxyribonucleic acid polymorphism in the apolipoprotein A-1-C-III gene cluster. Association with hypertriglyceridemia.

Authors:  A Rees; J Stocks; C R Sharpe; M A Vella; C C Shoulders; J Katz; N I Jowett; F E Baralle; D J Galton
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

4.  Strong association of a single nucleotide substitution in the 3'-untranslated region of the apolipoprotein-CIII gene with common hypertriglyceridemia in Arabs.

Authors:  S Taş
Journal:  Clin Chem       Date:  1989-02       Impact factor: 8.327

5.  Changing relative proportions of apolipoproteins CII and CIII of very low density lipoproteins in hypertriglyceridaemia.

Authors:  L A Carlson; D Ballantyne
Journal:  Atherosclerosis       Date:  1976 May-Jun       Impact factor: 5.162

6.  Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice.

Authors:  Y Ito; N Azrolan; A O'Connell; A Walsh; J L Breslow
Journal:  Science       Date:  1990-08-17       Impact factor: 47.728

7.  An apolipoprotein CIII marker associated with hypertriglyceridemia in Caucasians also confers increased risk in a west Japanese population.

Authors:  Q Zeng; M Dammerman; Y Takada; A Matsunaga; J L Breslow; J Sasaki
Journal:  Hum Genet       Date:  1995-04       Impact factor: 4.132

8.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.

Authors:  J D Dignam; R M Lebovitz; R G Roeder
Journal:  Nucleic Acids Res       Date:  1983-03-11       Impact factor: 16.971

9.  Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration.

Authors:  C L Malmendier; J F Lontie; C Delcroix; D Y Dubois; T Magot; L De Roy
Journal:  Atherosclerosis       Date:  1989-06       Impact factor: 5.162

10.  Human apolipoprotein CIII gene expression is regulated by positive and negative cis-acting elements and tissue-specific protein factors.

Authors:  K Reue; T Leff; J L Breslow
Journal:  J Biol Chem       Date:  1988-05-15       Impact factor: 5.157

View more
  70 in total

1.  Delineation of the insulin-responsive sequence in the rat cytosolic aspartate aminotransferase gene: binding sites for hepatocyte nuclear factor-3 and nuclear factor I.

Authors:  F Beurton; U Bandyopadhyay; B Dieumegard; R Barouki; M Aggerbeck
Journal:  Biochem J       Date:  1999-11-01       Impact factor: 3.857

Review 2.  Postprandial lipemia and coronary risk.

Authors:  W Patsch; H Esterbauer; B Föger; J R Patsch
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

3.  Differential regulation of gene expression by insulin and IGF-1 receptors correlates with phosphorylation of a single amino acid residue in the forkhead transcription factor FKHR.

Authors:  J Nakae; V Barr; D Accili
Journal:  EMBO J       Date:  2000-03-01       Impact factor: 11.598

Review 4.  Candidate genes and confirmed genetic polymorphisms associated with cardiovascular diseases: a tabular assessment.

Authors:  Z Tang; R P Tracy
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

5.  Consistency between cross-sectional and longitudinal SNP: blood lipid associations.

Authors:  Michael C Costanza; Sigrid Beer-Borst; Richard W James; Jean-Michel Gaspoz; Alfredo Morabia
Journal:  Eur J Epidemiol       Date:  2012-03-10       Impact factor: 8.082

6.  The effects of scale: variation in the APOA1/C3/A4/A5 gene cluster.

Authors:  Stephanie M Fullerton; Anne V Buchanan; Vibhor A Sonpar; Scott L Taylor; Joshua D Smith; Christopher S Carlson; Veikko Salomaa; Jari H Stengård; Eric Boerwinkle; Andrew G Clark; Deborah A Nickerson; Kenneth M Weiss
Journal:  Hum Genet       Date:  2004-04-24       Impact factor: 4.132

Review 7.  Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy.

Authors:  Richard J Woodman; Gerard T Chew; Gerald F Watts
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome.

Authors:  Michael Miller; Jeffrey Rhyne; Hegang Chen; Valerie Beach; Richard Ericson; Kalpana Luthra; Manjari Dwivedi; Anoop Misra
Journal:  Arch Med Res       Date:  2007-03-26       Impact factor: 2.235

Review 9.  Genetic determinants of plasma triglycerides.

Authors:  Christopher T Johansen; Sekar Kathiresan; Robert A Hegele
Journal:  J Lipid Res       Date:  2010-11-01       Impact factor: 5.922

10.  Identification and characterization of a novel 5 bp deletion in a putative insulin response element in the lipoprotein lipase gene.

Authors:  Li-Xia Yang; Hamid Razzaghi; John E Hokanson; M Ilyas Kamboh
Journal:  Biochim Biophys Acta       Date:  2009-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.